Cellsway Receives Investment from the Technology and Innovation Fund

Cellsway, a health-tech startup developing a microfluidics-based liquid biopsy platform, has received an investment from the Technology and Innovation Fund.

Previously, Cellsway had raised a €200,000 investment from APY Ventures in October 2023. Nearly a year later, the company has secured a new round of funding.

According to information shared by Türkiye Kalkınma Fonu, the investment agreement between the fund and Cellsway has been completed, although the financial details of the deal have not been disclosed.

The new funding will be used to complete product development and to ensure that the platform meets global compliance standards through FDA and CE-IVD certifications.

Founded by Prof. Dr. Haluk Külah, Dr. Özge Zorlu, Assoc. Prof. Dr. Ebru Özgür, and Prof. Dr. Tayfun Akın, Cellsway develops patented microfluidic technology that enables highly efficient isolation of circulating tumor cells (CTCs).

As an alternative to traditional solid biopsy methods used in cancer diagnosis, treatment, and monitoring, Cellsway’s platform not only isolates CTCs with high efficiency but also provides a portfolio of assays applied to these cells. This enables physicians to gain valuable insights for patient monitoring, drug selection, and treatment guidance.

The Technology and Innovation Fund stated that they are excited to support Cellsway’s growth and innovation processes, and emphasized their continued commitment to contributing to the country’s future through investments in deep technologies.